At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 100 enrolled
Drug / intervention
IBI305(Bevacizumab Biosimilar) +1 morebiological
Likely dose
IBI305(Bevacizumab Biosimilar) 3mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Compare IBI305 to Avastin on the Pharmacokinetics, Safety, Tolerance and Immunogenicity of a Single Dose In Healthy Male Subjects: a Randomized Double-blind Parallel Controlled Phase I Clinical Study
In Brief
A Phase 1 clinical trial evaluating IBI305(Bevacizumab Biosimilar) and Avastin(Bevacizumab) for Healthy. Completed, enrolled 100 participants across 1 site.
Detailed Summary
To confirm the PK similarity of IBI305 and bevacizumab in healthy volunteers .
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesChina
Collaborators--
Timeline
Phase 1CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartMar 2017
First PostedMar 2017
Primary CompletionAug 2017
TodayJul 2026
First PostedMar 20, 2017
Enrollment StartMar 9, 2017
Primary CompletionAug 17, 2017
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 9.3 years ago
Interventions
IBI305(Bevacizumab Biosimilar)biological
3mg/kg, infusion in 90minutes
Avastin(Bevacizumab)drug
3mg/kg, infusion in 90minutes